Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy

被引：0
|
作者：
S. Lautenschlaeger
C. Dumke
L. Exeli
H. Hauswald
R. Engenhart-Cabillic
F. Eberle
机构：
[1] Universitätsklinikum Marburg,Klinik für Strahlentherapie und Radioonkologie
[2] Marburg Ion-Beam Therapy Center (MIT),RNS Gemeinschaftspraxis
[3] St. Josefs-Hospital,Klinik für Radio
[4] Universitätsklinikum Heidelberg,Onkologie
来源：
Strahlentherapie und Onkologie | 2023年 / 199卷
关键词：
Radioresistant cancer; Salvage chemoradiation; Particle beam radiotherapy; RBE; Gastrointestinal cancers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：982 / 991
页数：9
相关论文
共 50 条
  • [31] Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV
    Öman, M
    Blind, PJ
    Naredi, P
    Gustavsson, B
    Hafström, LO
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (05): : 477 - 481
  • [32] A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin
    Daniel H. Palmer
    Deborah D. Stocken
    Helen Hewitt
    Catherine E. Markham
    A. Bassim Hassan
    Philip J. Johnson
    John A. C. Buckels
    Simon R. Bramhall
    [J]. Annals of Surgical Oncology, 2007, 14 : 2088 - 2096
  • [33] A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
    Palmer, Daniel H.
    Stocken, Deborah D.
    Hewitt, Helen
    Markham, Catherine E.
    Hassan, A. Bassim
    Johnson, Philip J.
    Buckels, John A. C.
    Bramhall, Simon R.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (07) : 2088 - 2096
  • [34] Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final results
    Pfeiffer, P.
    Ladekarl, M.
    Mortensen, M. B.
    Fromm, A-L.
    Bjerregaard, J. K.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [35] Gemcitabine (G) and carboplatin (C) as first line chemotherapy in patients with non-resectable non small cell lung cancer (NSCLC).
    Gomez, MD
    Casado, V
    Estevez, L
    Martin, ALI
    Castillo, M
    Robles, L
    Lobo, F
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 113 - 114
  • [36] Cytoreductive surgery for pancreatic cancer may improve overall outcome of gemcitabine-based chemotherapy.
    Pelzer, U.
    Bahra, M.
    Klein, F.
    Puhl, G.
    Denecke, T.
    Sinn, M.
    Stieler, J.
    Doerken, B.
    Neuhaus, P.
    Riess, H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 56 - 56
  • [37] Gemcitabine-based Concurrent Chemoradiotherapy Versus Chemotherapy Alone in Patients with Locally Advanced Pancreatic Cancer
    Wang, Bu-Hai
    Cao, Wen-Miao
    Yu, Jie
    Wang, Xiao-Lei
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (05) : 2129 - 2132
  • [38] Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer
    Klimant, Eiko
    Markman, Maurie
    Albu, Daniela M.
    [J]. CASE REPORTS IN ONCOLOGY, 2013, 6 (01): : 72 - 77
  • [39] Chemoradiotherapy versus gemcitabine-based chemotherapy in patients with unresectable, locally advanced pancreatic cancer.
    Nio, K.
    Ueno, H.
    Okusaka, T.
    Morizane, C.
    Hagihara, A.
    Kondo, S.
    Mayahara, H.
    Ito, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
    Kobayashi, Noritoshi
    Shimamura, Takeshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Endo, Itaru
    Ichikawa, Yasushi
    [J]. MEDICINE, 2017, 96 (19)
12345